Holen Sie sich die Stockscreener-App
199.98
0.16%
0.32
Handel nachbörslich:
199.98
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$199.66
Offen:
$199.96
24-Stunden-Volumen:
2.72M
Relative Volume:
0.53
Marktkapitalisierung:
$140.58B
Einnahmen:
$24.78B
Nettoeinkommen (Verlust:
$3.68B
KGV:
38.65
EPS:
5.1743
Netto-Cashflow:
$5.29B
1W Leistung:
+1.94%
1M Leistung:
+3.28%
6M Leistung:
-7.68%
1J Leistung:
+2.46%
1-Tages-Spanne:
$196.48
$201.34
1-Wochen-Bereich:
$192.62
$201.34
52-Wochen-Spanne:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
199.98 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
580.02 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
590.00 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
141.34 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
399.70 | 36.45B | 3.77B | 449.25M | 240.68M | 7.8556 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
Danaher Corp (DHR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
SCIEX Helps Clinical Labs Move From Sample to Answer Faster With New Software and LC Solutions - 01net
Danaher stock steadies on 2025 revenue and earnings - Ad-hoc-news.de
Danaher stock trades firm as recent earnings highlight diagnostics and life sciences growth - Ad-hoc-news.de
Danaher Corp (DHR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Why Are Danaher (NYSE:DHR) Latest Results Turning Heads? - Kalkine Media
Danaher (DHR) Maintains Buy Rating with $230 Price Target Amid M - GuruFocus
Danaher (DHR) Stock Tries To Steady After A Sharp Post Earnings Selloff - Yahoo Finance
Danaher Corp (DHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Danaher Corp (DHR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DHR|Danaher Corp|Price:191.500|Chg%:-1.000 - TradingKey
Danaher Corp (DHR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Danaher Corporation (DHR) Stock forecasts - Yahoo Finance UK
Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets - inkl
Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity - The Motley Fool
Danaher Corporation (DHR) Stock Forecasts - Yahoo Finance
Danaher Corp (DHR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Danaher Corp (DHR) Stock Up 7.5% and Still Undervalued -- GF Sco - GuruFocus
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Danaher Corp Stock (DHR) Moved Up by 6.78% on Jul 23: What Signal Does It Send? - TradingKey
Beckman Coulter Diagnostics Launches Fully Automated Urinalysis System to Meet Rising Testing Volumes - Financial Times
DHR Maintains Buy Rating -- Price Target Lowered to $236 by TD C - GuruFocus
DHR Maintained by Guggenheim -- Price Target Lowered to $200 - GuruFocus
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI - Bitget
TD Cowen cuts Danaher stock price target on bioproduction timing By Investing.com - Investing.com South Africa
Danaher stock trades steady as investors weigh life sciences growth and recent margin trends - Ad-hoc-news.de
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
Danaher Corporation (DHR) technical analysisDanaher (NYSE:DHR) - Benzinga
DHR Maintained by Wells Fargo -- Price Target Lowered to $195 - GuruFocus
Stifel cuts Danaher stock price target on bioprocess weakness By Investing.com - Investing.com South Africa
Stifel cuts Danaher stock price target on bioprocess weakness - Investing.com UK
Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says - marketscreener.com
Don't quit on Danaher stock after horrific earnings reaction - MSN
TD Cowen cuts Danaher stock price target on bioproduction timing - Investing.com
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Guggenheim cuts Danaher stock price target to $200 on bioprocessing concerns - Investing.com Nigeria
Danaher Q2 2026 Deep Dive: EPS Beats by 4.9%, Revenue Up 6% - AlphaStreet
Cepheid to Unveil Third-Generation GeneXpert® System at ADLM 2026, Advancing Molecular Diagnostic Capabilities - PR Newswire
Deutsche Bank Adjusts Danaher Price Target to $240 From $250, Maintains Buy Rating - marketscreener.com
Danaher Stock Fell 11% After Earnings. Here’s What Could Drive It in 2026 - TIKR.com
Danaher (NYSE:DHR) Returns To Value Stock Focus After Results Update - Kalkine Media
Danaher revenue up 5.5% to USD 6.3B in Q2 2026 - Medical Buyer
Danaher Shares Drop 11% After Biotech Division Growth Falls Short of Expectations, Forcing Valuation Adjustment - TechStock²
Danaher (DHR) Experiences Notable Decline Amid Market Fluctuatio - GuruFocus
Leerink Partners Adjusts Price Target on Danaher to $240 From $270, Maintains Outperform Rating - Moomoo
Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years - TIKR.com
Wells Fargo Adjusts Price Target on Danaher to $195 From $212, Maintains Equalweight Rating - marketscreener.com
Danaher (DHR) Experiences Significant Decline - GuruFocus
Danaher Shares Slide 11% as Valuation Drops Following Biotech Growth Miss - TechStock²
Guggenheim Adjusts Price Target on Danaher to $200 From $235, Maintains Buy Rating - marketscreener.com
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Danaher Corp-Aktie (DHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zerhouni Elias A. | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
46,484 |
0.00%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):